Lucid Diagnostics Inc. (LUCD) AI Stock Analysis

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company specializing in gastroesophageal reflux disease (GERD), also known as chronic heartburn or acid reflux. The company focuses on patients at risk of developing esophageal precancer and esophageal adenocarcinoma. Its portfolio includes EsoGuard, a laboratory developed test for esophageal DNA analysis, and EsoCheck, an advanced device for collecting esophageal cells. Founded in 2018 and headquartered in New York, New York, the company operates as a subsidiary of PAVmed Inc., developing diagnostic solutions to advance early disease detection and management.

Lucid Diagnostics generated revenue of $500,000 in FY2021, which dropped 24.6% to $377,000 in FY2022 before expanding 544.0% to $2.4M in FY2023. Revenue increased 79.0% to $4.3M in FY2024 and 8.3% to $4.7M in FY2025, delivering a 4-year revenue CAGR of 75.2%. However, profitability remains deeply negative; gross margin was -60.3% and operating margin was -1054.8% in FY2025, with net income of -$58.0M and EPS of -$0.46. For the trailing twelve months ending June 30, 2026, revenue was $5.4M, with quarterly revenue growing 26.7% year-over-year while operating margin stood at -868.5%.

As of June 30, 2026, Lucid Diagnostics held $33.4M in cash and short-term investments against total debt of $24.9M, resulting in net cash of $8.5M. The company had a current ratio of 1.33 and a debt-to-equity ratio of 2.28, supported by shareholders' equity of $10.9M and total assets of $38.9M. Operating cash flow in FY2025 was -$46.5M and free cash flow was -$46.5M. Capital expenditures were $197,000 in FY2025, while share issuance reached $272.0M, reflecting a 5-year share count change of 424.4%.

At a last close of $0.48, Lucid Diagnostics trades at a market capitalization of $91.3M and an enterprise value of $152.0M. Its price-to-sales multiple is 16.8x and its EV-to-revenue ratio is 27.9x, both higher than the median of its US-listed Healthcare peers, which carries a price-to-sales multiple of 4.1x. The company's price-to-book ratio is 14.7x. Over the past year, LUCD stock declined 61.1% compared to a 16.8% gain for the S&P 500 (SPY), and over five years the stock has fallen 94.9% while the benchmark gained 83.0%.

Wall Street coverage on Lucid Diagnostics includes 3 Strong Buy and 2 Buy recommendations, with 0 Hold, Sell, or Strong Sell ratings. The mean price target is $4.00, representing 736.8% upside versus the last close of $0.48. For the fiscal year ending December 31, 2026, analysts estimate revenue of $6.3M and EPS of -$0.24, reflecting 43.4% EPS growth. For the next fiscal year, 4 analysts estimate revenue will reach $16.7M, an increase of 165.2%, and EPS of -$0.17. The company logged 0 EPS beats over the last 4 quarters, with next earnings scheduled for November 11, 2026.

This page is an AI-written research summary of Lucid Diagnostics Inc. (LUCD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LUCD income statement, LUCD balance sheet, LUCD key metrics, LUCD analyst forecast, LUCD chart. See the LUCD stock overview for the latest quote and news.